幼年復發性呼吸道乳突狀瘤接受全身性貝伐單抗治療：單中心兒科病例系列

// Juvenile recurrent respiratory papillomatosis treated with systemic bevacizumab: A single-center pediatric case series

回顧13例JRRP（兒童呼吸道腫瘤），月用貝伐單抗5–10 mg/kg，10次後病灶縮小，76.9%完全緩解，年手術7.5→1.7｜氣切患兒均拔管，無嚴重不良事件；顯示貝伐單抗對難治JRRP有效、耐受佳，但需大型多中心研究確認療程與長期成效

// We retrospectively evaluated systemic bevacizumab for severe juvenile recurrent respiratory papillomatosis in 13 pediatric patients. Patients received monthly bevacizumab (5–10 mg/kg) and lesion volume and surgical rates were compared before and after treatment. After about 10 cycles, all patients had marked lesion reduction, 76.9% achieved complete remission, annual surgeries fell from 7.5 to 1.7, all tracheostomized children were decannulated, and no serious adverse events were reported. Systemic bevacizumab appears effective and well tolerated as adjuvant therapy for refractory pediatric JRRP, but larger multicenter studies are needed to define optimal duration and long-term outcomes.

Published 2026年9月23日